Skip to main
CNMD
CNMD logo

CONMED (CNMD) Stock Forecast & Price Target

CONMED (CNMD) Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 21%
Buy 29%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Conmed Corp reported strong financial performance with General Surgery sales growing by 8.7% to $206.9 million, surpassing consensus expectations, while Orthopedic Surgery sales increased by 2.4% to $139.0 million, also exceeding projections. The company demonstrated improved operating efficiency, with an operating margin increase of 280 basis points year-over-year to 18.6%, fueled by gross margin expansion and effective operating leverage. Additionally, Conmed's gross margin reached 57.6%, reflecting a 120 basis point year-over-year improvement and slightly exceeding previous estimates, indicating a solid trajectory for future profitability amid ongoing supply chain challenges.

Bears say

The financial outlook for Conmed Corp is negative, primarily due to anticipated revenue growth slowing to 4% or less, stemming from weaker AirSeal and Buffalo Filter sales and potential new product launch failures. Additionally, management has issued 2025 revenue and earnings per share guidance that falls below consensus estimates, citing ongoing supply chain challenges that are expected to impact margins. Furthermore, substantial revisions to revenue projections for 2025 and 2026 indicate a potential decline in the company's financial performance, reflecting a broader concern regarding its growth trajectory and overall profitability.

CONMED (CNMD) has been analyzed by 14 analysts, with a consensus rating of Buy. 21% of analysts recommend a Strong Buy, 29% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CONMED and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CONMED (CNMD) Forecast

Analysts have given CONMED (CNMD) a Buy based on their latest research and market trends.

According to 14 analysts, CONMED (CNMD) has a Buy consensus rating as of Jul 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $91.57, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $91.57, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CONMED (CNMD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.